Vantia Therapeutics announces £4 million fund raising
6 July 2011
Vantia Therapeutics raises £4 million to fund clinical development of lead compounds.
Vantia appoints new CEO
9 June 2010
Vantia Therapeutics announces that it has appointed Andrew Crockett to the position of Chief Executive Officer.
MVM Life Science Partners
MVM Life Science Partners LLP, founded in 1997, is one of the UK's leading Venture Capital firms and manages three funds totalling over US$500 million. MVM invests across the Life Sciences market including biopharmaceuticals, diagnostics, drug delivery, gene therapy, medical devices, OTC medicines, research tools and vaccines. MVM invests predominantly in start up and early stage companies based across Europe and in the US. The MVM team has broad experience across the Life Science and Venture Capital markets and maintains offices in London and Boston. Click here for more information: www.mvmlifescience.com.
SV Life Science Partners
SVLS is a life sciences-focused venture capital business and SV Life Sciences Managers LLP is the Manager of IBT. SVLS funds invest in companies requiring funding within the human life sciences sector including biotechnology and pharmaceutials, medical devices and instruments, healthcare IT and services. SVLS advises or manages four venture capital funds and the publicly traded investment trust – International Biotechnology Trust plc with total capital of approximately $1.6 billion that invest in life sciences companies at all stages of development. SVLS has 29 professionals and has invested in over 175 companies over the course of the last decade making SVLS one of the lagest and most active healthcare investors in the world. SVLS was established in 1993 and currently has offices in London, Boston and San Francisco. Click here for more information: www.svlsa.com.
SVLSFIV and International Biotechnology Trust (IBT.L) are the SVLS-managed funds which have invested in Vantia Therapeutics.
Novo A/S is an active and independent company in its support of biotech ventures. The aspiration is to bring together the best of both worlds: industry insight and network from our pharma/biotech inheritance combined with a venture capital mindset that focuses on results and value creation. Novo A/S' portfolio of investments in life science has grown considerably since the company's start. Today the portfolio comprises close to 50 companies. There is considerable diversity in the portfolio across technologies, products and financial stages. Furthermore, the portfolio is international, currently with more than half the invested capital in North American companies and the rest in Denmark and Europe.
Ferring is a Swiss-based, research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and now has offices in over 40 countries. Click here for more information: www.ferring.com.